Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079306 | 0.87 | PTGS1 (0.53) | BCAT2PTGS1MAPK14PTGS2 | |
| SCHEMBL27353967 | 0.84 | BCAT2 (0.69) | BCAT2PTGS1MAPK14PTGS2 | |
| SCHEMBL1670982 | 0.82 | BCAT2 (0.72) | BCAT2 | |
| SCHEMBL6664795 | 0.81 | BCAT2 (0.51) | BCAT2PTPN1 | |
| SCHEMBL27749147 | 0.81 | BCAT2 (0.51) | BCAT2PTPN1 | |
| SCHEMBL1339762 | 0.81 | BCAT2 (0.51) | BCAT2PTGS2 | |
| SCHEMBL6497992 | 0.81 | CYP2C8 (0.48) | BCAT2PTGS2 | |
| SCHEMBL24508434 | 0.80 | BCAT2 (0.50) | BCAT2 | |
| SCHEMBL982263 | 0.79 | SMN1; SMN2 (0.54) | BCAT2PTGS2PTPN1 | |
| SCHEMBL2562025 | 0.79 | PTGS1 (0.51) | BCAT2PTGS1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126189-A | 3-thio-3- (trimethylsilyl) -1-ketone compound, preparation method and application thereof | 南京工业大学 | 2023-11-28 | — | — | CN | claimed |
| US-8063099-B2 | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-22 | — | — | US | disclosed |
| EP-2185512-B1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | disclosed |
| CN-101790515-A | trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD | 2010-07-28 | — | — | CN | disclosed |
| EP-2185512-A2 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016560-A2 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-05 | — | — | WO | disclosed |
| CN-1059142-A | New thiophene derivant | FUJISAWA PHARMACEUTICAL CO (JP) | 1992-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | BCAT2 3798/4885PTGS1 1952/4885BCL2L1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.